FINWIRES · TerminalLIVE
FINWIRES

L3Harris Technologies在第一季度业绩超预期后,上调了2026年盈利预期。

By

-- L3Harris Technologies (LHX) 周四上调了全年盈利预期,此前该公司公布的第一财季业绩超出预期,各业务板块销售额均实现增长。 这家航空航天和国防技术公司目前预计2026年每股收益为11.40美元至11.60美元,高于此前11.30美元至11.50美元的预期。FactSet调查的分析师预期为11.59美元。L3Harris继续预计全年营收在230亿美元至235亿美元之间,而华尔街的预期为234.4亿美元。 首席执行官克里斯托弗·库巴西克在一份声明中表示:“我们今年开局强劲,订单和营收均实现稳健增长,同时各项战略重点也取得了进展。” 截至4月3日的第一财季,每股收益从去年同期的2.04美元增至2.72美元,高于市场普遍预期的2.53美元。营收增长12%至57.4亿美元,高于华尔街此前预期的54.2亿美元。 空间与任务系统部门的销售额增长24%至29.9亿美元,导弹解决方案部门的销售额增长18%至9.9亿美元。通信与频谱优势部门的营收增长3%至18.6亿美元。 据FactSet发布的财报电话会议记录显示,库巴西克在财报电话会议上表示:“全球安全环境正在快速变化,这对我们的客户的影响也日益清晰。在中东、欧洲和印太地区,威胁环境正在促使人们更加迫切地需要提升战备能力、增强韧性并实现现代化。” 周三晚些时候,L3Harris表示,已向美国证券交易委员会秘密提交了一份注册声明草案,计划将其导弹解决方案业务进行首次公开募股(IPO)。IPO的规模和定价细节尚未确定。今年早些时候,该公司表示美国政府计划向其导弹解决方案部门投资10亿美元。 “此次IPO不仅实现了对Aerojet收购的收益,还打造了一家纯粹的导弹/推进飞行器公司,并获得了前所未有的(美国战争部)锚定投资,”韦德布什证券公司周四在一份致客户的报告中表示。“我们认为这是一个积极的信号;随着IPO定价前景的明朗化以及市场对(导弹解决方案)业务进行分部估值,股价应该会受益。” 周三,通用动力公司(GD)在公布第一财季业绩超出华尔街预期后,上调了全年盈利预期。此前,洛克希德·马丁公司(LMT)公布的3月季度业绩不及华尔街预期,而其他航空航天和国防公司RTX(RTX)和诺斯罗普·格鲁曼公司(NOC)的业绩则超出预期。

Price: $320.70, Change: $-0.70, Percent Change: -0.22%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM